Transpire Bio Achieves Important Corporate Milestone with Dosing of First Human Subject in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program

News Transpire Bio Achieves Important Corporate Milestone with Dosing of First Human Subject in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program WESTON, Fla., Dec 17, 2024 (GLOBE NEWSWIRE) Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a definitive agreement with […]